Research Article - (2020) Volume 14, Issue 5
Introduction: The aim of this review is to hypothesize the mechanism of action of chlorine dioxide in COVID-19 by studying its mechanism of action in the structure of SARS-CoV-2.
Methods: Reviews of research on the mechanism of action of chlorine dioxide in viruses, particularly SARS-CoV-2and influenza viruses at the amino acid level in the viral spike were conducted and these data were transferred to the same structural amino acids of SARS-CoV-2. We used 3D computer reconstructions, use of data through cryo-electronic studies, and previous work based on ChimeraX (UCSF) augmented reality software.
Results: The projection and simulation of chlorine dioxide oxidation in structural amino acids of SARS-CoV-2 allows inferring the sites in which chlorine dioxide exerts a denaturalizing action on viral structure and on human ACE2 as well as it is possible to understand the extreme speed with which it acts, which could explain the first findings of clinical observational studies of chlorine dioxide use in COVID-19 carried out by the authors in Bolivia under strict compliance of ethics committee.
Conclusion: The oxidation by chlorine dioxide of critical amino acids in the spike of the coronavirus SARS-CoV-2 and in the structure of ACE2 allows us to understand the potentially therapeutic actions of chlorine dioxide dissolved in water by oral way in the COVID-19. We hope to publish clinical application trials of this promising systemic virucide soon.
SARS-CoV-2 • COVID-19 • Aminoacids • Chlorine dioxide
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. It was first detected in the Chinese city of Wuhan (Hubei province) in December 2019. In three months it spread to basically all countries in the world, which is why the World Health Organization declared it a pandemic. (WHO, March 11, 2020).
There is no specific treatment; the main therapeutic measures are to relieve symptoms and maintain vital functions. Research to find an effective treatment began since the pandemic scale of the disease was verified. The central problem is that, eleven months after its official onset, an effective treatment for the disease is still unknown. In the absence of an effective treatment, we studied new therapeutic possibilities with the intention of finding an effective and safe treatment for COVID-19.
In accordance with the above, this research addresses current results and previous research adding the possible therapeutic action as a virucidal of chlorine dioxide in aqueous solution and without the presence of sodium chlorite using the concepts of translational medicine based on knowledge about the structure of the virus and the mechanism of action of chlorine dioxide in viruses, to propose a possible treatment of choice for COVID-19 [1,2].
The action of chlorine dioxide is given by its selectivity for pH and by the area or size where it generates its action. It means that this molecule dissociates and releases oxygen when it comes into contact with another acid . Upon reacting, its chlorine atom binds to sodium in the medium and turns into sodium chloride (common salt) releasing oxygen, which oxidizes the acidic pH pathogens present, converting them to alkaline oxides. Therefore, when chlorine dioxide dissociates, it releases oxygen into the blood, as erythrocytes (red blood cells) do by the same principle (known as the Bohr effect), which is to be selective for acidity.
As it normally happens in blood, chlorine dioxide releases oxygen when it encounters acidic soil, be it lactic acid or the acidity of the pathogen. Its possible therapeutic effect is postulated due, among other effects, to the fact that it creates an alkaline environment, while eliminating small acid pathogens, by oxidation, with an electromagnetic overload that is impossible to dissipate by unicellular organisms. The death time in a virus must be analogous to the lag time caused by the chemical reaction, due to the times required to cover the entire volume. We can expect that in a virus with a diameter of 120 nanometers, the destruction time will be much shorter due to its geometric factor.
According to studies by Zoltán Noszticzius, chlorine dioxide is a sizeselective antimicrobial agent that can quickly kill micrometer-sized organisms, but cannot cause real harm to much larger organisms such as animals or humans, as it cannot penetrate deep into their tissues.
It is known that multicellular tissue has the highest capacity to dissipate electrical charges and therefore is not affected in the same way by the voltages of the oxidation-reduction process (ORP) as is the case of unicellular organisms and therefore there is biochemically speaking, a greater cell protection because of size.
Chlorine dioxide, which is the most effective non-cytotoxic disinfectant known after ozone, and used as an aqueous solution has immense possibilities of being used therapeutically since it is also capable of penetrating and eliminating biofilm, which ozone does not do . The great advantage of the possible therapeutic use of chlorine dioxide in infections is the impossibility of a bacterial or viral resistance to ClO2 since it has an oxidation mechanism unlike chlorine (Cl2) which acts by chlorination .
Although ozone is stronger in antiseptic terms, its high oxidative potential of 2.07 and its short half-life of only 15 minutes at 25°C with a pH value of 7.0 makes it less effective than ClO2 for therapeutic applications in vivo. Chlorine dioxide is pH (-) and a size selective oxidant and, unlike other substances, it does not react with most components of living tissues (3). Chlorine dioxide reacts rapidly with phenols and thiols essential for bacterial life.
In phenols, the mechanism consists in the attack of the benzene ring, eliminating odor, taste and other intermediate compounds . Chlorine dioxide kills viruses effectively and is up to 10 times more effective than sodium hypochlorite (bleach or bleach). It was also shown to be very effective against small parasites, protozoa . One topic that has been reviewed a lot lately is the reactivity of chlorine dioxide with amino acids. In tests for reactivity of chlorine dioxide with 21 amino acids, only cysteine , tryptophan , tyrosine , proline and hydroxyproline reacted at a pH of around 6.
Cysteine and methionine (4) are two aromatic amino acids that contain sulfur, tryptophan and tyrosine and the two inorganic ions Fe2+ and Mn2+ . Cysteine, because it belongs to the group of thiols, is an amino acid up to 50 times more reactive with all microbial systems than the other four amino acids and, therefore, it is impossible for it to create resistance against chlorine dioxide.
The hypothesis we propose here is that the cause of the antiviral effect of chlorine dioxide can be explained by its actions on at least five amino acids listed above or on peptide residues.
Chlorine dioxide (ClO2) has been used since 1944 in the treatment of drinking water due to its biocidal power, as well as in most bottled waters suitable for human consumption due to its almost zero lack of toxicity in an aqueous solution being used systematically in the disinfection and conservation of blood transfusion bags [3,4]. As it is a selective oxidant, its mode of action is very similar to that of phagocytosis, where a mild oxidation process is used to eliminate all types of pathogens [3,4].
Chlorine dioxide (ClO2) is a yellowish gas that to date is not part of the conventional pharmacopoeia as a medicine despite its proven effectiveness in denaturing viruses, with multiple patents for use in different treatments such as disinfection or sterilization of blood components (blood cells, blood proteins, etc.) 4, the parenteral treatment (intravenous route) of HIV infections, or for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's and other patents for uses such as patents for: apoptosis induction cancer treatment (CN 103720709 A) tumor treatment (US 10, 105, 389 B1) Sinusitis antiviral treatment (US 2o16/0074432 A1), System stimulation immunological (US 5,830,511),Stem cell initiation and differentiation (WO2014082514A1), Vaginal treatment method (US 6280716B1), Skin treatment against viruses and bacteria (US 4,737,307), Human amoebiasis treatment method (US 4,296,102), Treatment against candidiasis infections ( US 2015/0320794 A1), Wound treatment (US 87.3106), Oral cavity treatment (US 100015251), (US4689215), Against inflammations (US53841134), Nail fungus treatments (US 20100159031) and Against inflammations (US53841134), Treatments against nail fungus (US 20100159031) and Against inflammations (US53841134), Treatments against nail fungus (US 20100159031) and Swiss patent pending/11136-CH. (Kalcker, A.) .
Based on the above, three premises can be established:
1. Chlorine dioxide can fight viruses through the selective oxidation process by denaturing capsid proteins and subsequent oxidation of the virus's genetic material, rendering it disabled. As there is no possible adaptation to the oxidation process, it prevents the development of resistance by the virus, making chlorine dioxide (ClO2) a promising treatment for any viral subspecies.
2. There is scientific evidence that chlorine dioxide is effective against the SARS-CoV-2  and SARS-CoV-2 coronavirus, such as the work carried out at the University of Queretaro in Mexico and published in November 2020 COVID-19, called "In vivo evaluation of the antiviral effect of ClO2 (chlorine dioxide) in chicken embryos inoculated with avian coronavirus (IBV), in which ClO2 treatment had a marked impact on IBV infection. Namely, viral titers were 2.4 times lower and mortality was halved in infected embryos that were treated with ClO2. The infection caused developmental abnormalities regardless of treatment. Lesions typical of IBV infections were observed in all inoculated embryos, but the severity tended to be significantly less in ClO2-treated embryos. No macro or microscopic evidence of toxicity caused by ClO2 was found at the doses used.
3. Toxicity: The biggest problems that arise with drugs or substances that can be considered as such in general are due to their toxicity and side effects. There is toxicity with chlorine dioxide in case of respiratory inhalation, but there are no reports of toxicity at the recommended dose of 30 mg or 30 ppm in aqueous solution when taken orally and no clinically proven death even at high doses by oral ingestion. The lethal dose (LD50, acute toxicity ratio) is estimated at 292 mg per kilo for 14 days, where its equivalent in a 50 kg adult would be 15,000 mg administered over two weeks. The sub-toxic oral doses that can be used are approximately 50 ppm dissolved in 100 ml of water 10 times a day, which is equivalent to 500 mg. Furthermore, chlorine dioxide, by dissociation, it decomposes into a chlorine ion that immediately associates with the sodium ion, forming common salt NaCl and oxygen O2 within the human body. In summary, chlorine dioxide at the recommended doses in COVID-19 of 30 mg or 30 ppm per day is not toxic [5-8].
Virucidal effects of chlorine dioxide
Chlorine dioxide is an effective antimicrobial agent that kills bacteria, viruses, and some parasites . Its broad spectrum germicidal profile is derived from the action of this compound as a non-cytotoxic oxidant.
Viruses generally consist of an outer layer or a protein coat that encapsulates a nucleic acid, which can be DNA or RNA. When chlorine dioxide comes in contact with a virus, a single, highly reactive nascent oxygen atom is released on the target virus. This oxygen binds to specific amino acids in the protein coat of the virus, denaturing the proteins and rendering the virus inactive. Additionally, nascent oxygen atoms bind to guanine, one of the four nucleic acid bases found in RNA and DNA, forming 8-oxoguanine. This oxidation of guanine residues prevents viral nucleic acid replication .
In the published scientific literature there are reports that chlorine dioxide inactivates a wide variety of viruses, including influenza A, human adenovirus, human rotavirus, echovirus, bacteriophage f2, and poliovirus [11-16].
Influenza A viruses are spherical, negative-sense, single-stranded RNA viruses that possess a lipid membrane that contains peaks composed of glycoproteins known as HA (hemagglutinin) and NA (neuraminidase). Within the virus there are eight single strands of RNA . A preclinical study found that chlorine dioxide gas is effective in preventing aerosol-induced influenza A virus infection. This study used low concentrations of chlorine dioxide gas (ie 0.03 ppm) in a mouse cage. This level is below the OSHA long-term exposure level (8 hours) for chlorine dioxide gas in ambient air in a human workplace, which is 0.1 ppm . Chlorine dioxide gas effectively reduced the number of infectious viruses in the lungs of mice and markedly reduced mortality. Mortality was 70% (7/10) on day 16 in the group not treated with chlorine dioxide and 0% (0/10) in the group treated with chlorine dioxide. The authors confirmed these results by repeating their experiment. The results of the repeat study were 50% (5/10) mortality in the untreated group and 0% (0/10) in the treated group.
The authors concluded that low levels of chlorine dioxide gas (i.e., 0.03 ppm), which are below the permissible exposure level in human workplaces, "could be used in the presence of humans to prevent their infection by influenza A virus and possibly other viruses associated with tract infections respiratory (p. 65). They suggested that "chlorine dioxide gas could be used in places like offices, theaters, hotels, schools and airport buildings without evacuating people, without disrupting their normal activities." The authors suggested that their method "opens a new path for the prevention of pandemic influenza" (p. 65) after conducting a study in a school with favorable results in this regard.
The infectivity of the virus was found to be reduced in vitro by the application of chlorine dioxide, and higher concentrations produce even greater reductions. This inhibition of infectivity was correlated with alterations in viral proteins. These alterations resulted from the incorporation of oxygen atoms in the tryptophan and tyrosine residues located in the HA and NA proteins . These proteins are denatured by the addition of oxygen atoms, which eliminates the ability of the virus to infect other cells . A later study found that influenza A virus inactivation is caused by the transfer of 2 oxygen atoms from chlorine dioxide to a specific tryptophan (W153) residue in the hemagglutinin (HA) tip protein .
Adenoviruses are non-enveloped viruses with an icosahedral capsid containing a double-stranded DNA genome. Seven groups of human adenoviruses have been classified . A recent study found that chlorine dioxide can help reduce adenovirus levels in drinking water . This study examined the effects of chlorine dioxide and ultraviolet light on adenovirus levels in drinking water in the Netherlands. The authors found that the application of chlorine dioxide in low concentrations (0.05 - 0.1 ppm) reduced adenoviruses in drinking water, while UV disinfection was insufficient without chlorine dioxide disinfection.
Rotaviruses are double-stranded RNA viruses that consist of 11 unique double-stranded RNA molecules surrounded by a three-layered icosahedral protein capsid . These viruses, which are the leading cause of severe diarrheal diseases in infants and young children worldwide, are inactivated by chlorine dioxide. In fact, at concentrations of chloride dioxide ranging from 0.05 to 0.2 ppm, they are inactivated within 20 seconds in vitro [23,24].
Bacteriophage f2 is a positive sense single-stranded RNA virus that infects Escherichia coli bacteria. An in vitro study found that 0.6 mg/liter of chlorine dioxide rapidly (i.e., within 30 seconds) inactivated bacteriophage f2 and interfered with its ability to bind to its host, E. coli . Both the inactivation of the virus and the inhibition of its ability to bind to its host increased with higher pH and with increasing concentrations of chlorine dioxide. Additionally, the authors found that chlorine dioxide denatures virus capsid proteins by reacting with tyrosine, tryptophan, and cysteine residues. These amino acids were almost completely degraded within 2 minutes of exposure to chlorine dioxide.
Poliovirus is a positive-sense, positive-strand RNA virus . Ridenour and Ingerson found that chlorine dioxide can inactivate polio virus in vitro. Later, Álvarez and O'Brien expanded this work by showing that treatment with 1 ppm of chlorine dioxide in vitro results in the separation of RNA from the capsid and also produces alterations in the RNA [16,26].
In addition to the studies mentioned above, the US Environmental Protection Agency (EPA), which on April 10, 2020 listed chlorine dioxide as an EPA-registered disinfectant to kill the SARS-CoV-2 virus, provides additional support for the virucidal effects of chlorine . The EPA website indicates that this product is for surface use and not for human use.
Human studies on the effects of chlorine dioxide on the SARS-CoV-2 virus have not yet been conducted. Currently, two of the authors (Insignares and Bolano) are conducting the first multicenter clinical trial in the world on the effectiveness of oral chlorine dioxide in humans in COVID-19 (ClinicalTrials. gov identifier: NCT04343742). An in vitro study found that chlorine dioxide inactivates the genetically related SARS-CoV-2virus . A concentration of 2.19 mg/liter of chlorine dioxide was found to cause complete inactivation of SARS-Co-V in wastewater. A branch of our group is in the process of conducting an in vitro investigation of the action of chlorine dioxide on SARS-CoV-2 in India and we are in the process of publishing a report on the simulation of the mechanism of action of chlorine dioxide in SARS-Co-V-2 using the in silico method, carried out in Japan.
In Ecuador (Aememi) for Chlorine dioxide, an effective therapy for the treatment of COVID-19; 51) A preliminary trial was carried out with the administration of oral chlorine dioxide on 104 COVID-19 patients who had variable profiles in terms of age, sex and severity of the disease, the minority diagnosed by testing and the majority by screening according to typical symptoms of the illness. Therefore, the data were managed using a symptomatic scoring scale, with 10 being the maximum perception and 0 being the minimum of the symptom: fever, chills, muscle pain, dry cough, headache, back pain, difficulty breathing, vomiting, diarrhea, sore throat, loss of smell, loss of taste, poor appetite.
Chlorine dioxide in a concentration of 3000 ppm was recommended at a dose of ten cc diluted in one liter of water, taken throughout the day, divided into 10 daily doses, taken every hour and a half for 20 days. The results were distributed according to the symptoms after the first, second, third and fourth treatment days. They were segmented between men and women, and common results were also presented. The following tables show the symptoms, and in the first and last graph the behavior in relation to the symptomatological scale between the first and fourth day of oral chlorine dioxide intake (Figures 1 - 4).
From this preliminary study the following conclusions can be drawn: Chlorine dioxide is definitely harmless - not toxic at all - in the recommended and ingested doses and all initial symptoms began to decrease from the first day of treatment, the decrease being totally evident on the fourth day. Specifically, symptoms most indicative of an ongoing infection, such as fever, chills, headache, sore throat, loss of appetite, and loss of the senses of taste and smell, were dramatically decreased. Other symptoms, such as muscle pain and cough, remained somewhat common, as they tend to remain residual for longer after the illness has ended.
To search for the reference information used in this article, the web search engines were reviewed using the MesH criteria, in accordance with the search strategy indicated in subsequent lines in the periods between January and April 2020, finding the following results: 1. PubMed (Medline): 4 references, 2. LILACS: 18 references, 3. Cochrane Library: 56 references, 4. Science: 1,168 references, 5. Scielo: 61 references, 6. MedScape: 19 references for a total of 1,326 scientific publications whose contents were on the use of chlorine dioxide in different applications and on the mechanism of action of chlorine dioxide in the SARS-CoV-2 viruse. Finally, we reviewed the registries at www.clinicaltrials.gov and those of the WHO International Clinical Trials Registry Platform (ICTRP) in order to identify ongoing or unpublished clinical trials.
"Chlorine dioxide" OR "Chlorine dioxide protocol" OR Chlorine dioxide AND virus; Chlorine dioxide AND SARS-COV-2; OR "COVID-19 drug treatment" OR "spike glycoprotein, COVID-19 virus" OR "severe acute respiratory syndrome coronavirus 2" OR "COVID-19" OR "2019-nCoV" OR "SARS-CoV-2" O " 2019 new coronavirus "OR" 2019 coronavirus disease "OR (pneumonia).
From the search results, we selected those that made reference to the virucidal action of chlorine dioxide on various microorganisms, in particular on viruses and, among these, SARS-CoV-2 or SARS-CoV.
We also reviewed the studies carried out on the action of chlorine dioxide on amino acids, especially those that are part of viral capsids. From the findings we highlight that in 1986, Noss et al. demonstrated that the inactivation of bacterial virus (bacteriophage) f2 by ClO2 was due to its reactions with viral capsid proteins. Additionally, they found that three amino acids of the viral protein, namely cysteine, tyrosine and tryptophan, could react with ClO2 rapidly . In 1987, Tan and others tested the reactivity of ClO2 at 21 free amino acids . The ClO2 reacted with only six amino acids dissolved in 0.1 M sodium phosphate buffer at pH 6.0. The reaction with cysteine, tryptophan and tyrosine was too rapid to be followed by his technique.
The reactivity of the three fast-reacting amino acids (cysteine, tyrosine and tryptophan were studied in the laboratory between 2005 and 2008, finding that cysteine had the highest reactivity among these three amino acids [30,31].
In 2007, Ogata discovered that the antimicrobial activity of ClO2 is based on the denaturation of certain proteins, which is mainly due to the oxidative modification of the tryptophan and tyrosine residues of the two model proteins (bovine serum albumin and glucose - 6- phosphate dehydrogenase) used in their experiments . In 2012, it was again Ogata who demonstrated that the inactivation of the influenza virus by ClO2 was caused by the oxidation of a tryptophan (W153) residue into hemagglutinin (a protein from the spike of the virus), thus suppressing its ability to bind to receptors .
In this context, it is interesting to note that the spike protein of the new coronavirus SARS-CoV-2 contains 54 tyrosine residues, 12 tryptophan and 40 cysteine .
If we assume that in an aqueous solution all these amino acid residues are capable of reacting with ClO2 as well as with free amino acids, the inactivation of the virus can be extremely rapid even in a solution of 0.1 mg/L of ClO2.
On the other hand, we selected the articles that describe the action of SARS-CoV-2 in cells, in its interaction with ACE2 and, in particular, we investigated augmented reality videos or simulation videos based on Silico, for three-dimensional representation. From action sites like videos in which the spicular protein and the ACE2 receptor, among others, are manipulated with ChimeraX (UCSF) augmented reality software [34-41].
In the same way, we reviewed the structure of the virus spike and based on research from Daniel Wrapp and Jason S. McLellan at the University of Texas.
The three-dimensional image of the spicular S glycoprotein of the SARSCoV- 2 betacoronavirus has been seen with electron cryomicroscopy in record time. Thanks to this image with a resolution of 3.5 Å, it is confirmed that this S protein is coupled to the hACE2 protein of human cells with a higher affinity than that of the SARS-CoV-2coronavirus. Protein S is the target of the antibodies that immunize us. Its 3D structure makes it possible to understand why published monoclonal antibodies against SARS-CoV-2are not effective against SARS-CoV-2. It will undoubtedly help accelerate the development of vaccines and therapies against COVID-19 infection .
In these simulation and virtual reality videos, it is observed that protein S is a trimer made up of three peptides, each with two subunits S1 and S2. The S1 subunit acts as a hinge with two conformations called "down" (RBD down) and "up" (RBD up). Electron cryomicroscopy imaging shows that only one of the peptides is in the "up" state, while the other two are in the "down" state. Binding to the cellular receptor occurs in the "upstream" configuration. After binding, the three protein S peptides are cleaved at the S1/S2 site; a second split then occurs at the S2 'point, unfolding the key fusion peptide (FP) at the junction between the membranes.
The spicular protein (S) is a type I transmembrane trimeric protein with between 1,160 and 1,400 amino acids, depending on the type of coronavirus. This protein forms the coronavirus corona; It is composed of three repeating peptides and is highly glycosylated, which facilitates its binding to proteins and sugars. Each peptide is made up of two domains called S1 and S2. In beta coronaviruses like SARS-CoV-2, cleavage of the S1 and S2 subunits occurs during fusion between the membranes.
The S1 domain has two subdomains, one N-terminal (NTD), which ends with an amino acid that has a free amino group (-NH2), and another C-terminal (CTD), which ends with a carboxyl group (-COOH); both bind to the host cell's ACE2 receptor, then they are receptor-binding domains (RBD). The S2 domain is C-terminal in type and is highly conserved among all coronaviruses, which differ much more in the S1 subunit. The S2 domain contains two regions, HR1 and HR2, in which groups of seven amino acids (called heptides) repeat, in abcdefg form, that contain a and d hydrophobic residues that participate in the fusion between the membranes. The HR1 and HR2 domains are therapeutic targets, since drugs are known that inhibit their action, preventing or hindering fusion.
The infection of the epithelial cells of the respiratory tract is orchestrated by the S protein of the virus. In the general steps of the fusion process first, the S1 domain recognizes and binds to the host cell receptor. Second, there is a first split at the S1 and S2 domains, and a second split at the S2 'point; the latter allows the fusion peptide (FP) that connects the membranes of the host and the virus to be activated (this stage is called the intermediate stage of fusion or intermediate stage of fusion). And third, the region between HR1 and HR2 remodels (folds) giving rise to a heptamer (6-HB) that joins both membranes allowing the entry of the virus.
The S protein of coronaviruses is key in the development of vaccines (antigens that induce an immune response to the presence of the S1 domain) and for the development of antivirals (inhibitors of some of the fusion stages between membranes, normally attacking specific regions of the domain S2). Knowing the three-dimensional structure of protein S is essential to combat the COVID-19 epidemic.
The sequence of the protein S of SARS-CoV-2 coincides 98% with the protein S of the coronavirus Bat-RaTG13, with the great difference that it has four RRAR amino acids (arginine-arginine-alanine-arginine) instead of just one arginine (R). Furthermore, they differ in 29 residues, 17 of which are in the RBD region. The comparison made between the 61 complete SARS-CoV-2 genomes available in GISAID (Global Initiative to Share All Influenza Data) shows that there are only 9 different amino acids between all of them; and all these variants are found in very well preserved places, which does not seem to affect the lethality of the coronavirus.
First, it was possible to characterize the 3D structure of the spicular S glycoprotein of the SARS-CoV-2 coronavirus and its RBD receptor binding domain. Then that of the host cell receptor, the human angiotensin-converting enzyme hACE2. The next step for the researchers was to determine the structure of the SARS-CoV-2 RBD/hACE2 complex, which were obtained by X-ray crystallography, reaching resolutions of 2.45 Å and 2.68 Å. Among the findings, it was determined that very subtle structural changes explain the higher infectivity and pathogenesis of SARS-CoV-2 (COVID-19) compared to SARS-CoV-2 (SARS).
These findings are of great relevance for the development of drugs to combat COVID-19. In silico reconstructions have been carried out (using theoretical models using computers), but observation of the real crystallographic structure by X-ray diffraction is essential. As noted at the outset, the authors are in the process of publishing the Japan-based in silico study they conducted on the mechanism of action of chlorine dioxide on the SARS-CoV-2 spike and hemoglobin.
The first problem that arises in the research process is how to form the SARS-CoV-2 RBD/hACE2 complex with sufficient stability for its observation; Previous experience in the formation of the SARS-CoV-2RBD/hACE2 complex (evidenced in 2005) has been key, in which a salt bridge between Arg426 of RBD and Glu329 of hACE2 is used to reinforce the binding of the complex. A very important observation is that cysteine at positions Cys336-Cys361, Cys379-Cys432 and Cys391-Cys525 stabilize the five beta sheets (β1, β2, β3, β4 and β7), and Cys480-Cys488 is key in the junction between the ridge SARS-CoV-2 RBM and the N-terminal helix of hACE2 [43-45].
When the simulation of the action of dioxide on these amino acids (Cys) is placed, it is easy to understand the fabulous direct virucidal effect of dioxide on viruses and in particular on SARS-CoV-2. The image that is revealed is of a devastating effect of chlorine dioxide on the virus, degrading and denaturing it. Comparison between SARS-CoV-2RBD/hACE2 and SARS-CoV-2 RBD/ hACE2 complexes provides insight into why COVID-19 is more infectious than SARS-CoV.
SARS-CoV-2 RBM forms a larger and more highly contacted junction interface with hACE2 than SARS-CoV-2RBM; the salt bridge between SARSCoV- 2RBD and hACE2 is weaker than between SARS-CoV-2 RBD and hACE2. The crystal structure of the complex also contains glucans coupled to the four hACE2 sites and the RBD site. The glucan coupled to Asn90 from hACE2 forms a hydrogen bond with Arg408 in the core of RBD; this interaction is conserved between SARS-CoV-2 and SARS-CoV.
The structural differences between the RBMs of SARS-CoV-2 and SARSCoV are subtle, but affect the conformations of the loops in the receptorbinding ridges. In both RBMs, one of the ridge bonds contains a disulfide bond that is critical for bonding. SARS-CoV-2and bat-CoV Rs3367 contain a motif with three Pro-Pro-Ala residues in said loop; but in SARS-CoV-2 and bat-CoV RaTG13 show a motif of four Gly-Val/Gln-Glu/Thr-Gly residues; therefore, the conformation of the loop changes because the glycines are more flexible. This change favors the RBD/hACE2 binding. Furthermore, the ridge has a more compact conformation thanks to the Asn487 and Ala475 hydrogen bonds in SARS-CoV-2 RBM, bringing the loop containing Ala475 closer to hACE2.
The contact of the crest of SARS-CoV-2 RBM with the N-terminal helix of hACE2 is greater than for SARS-CoV-2RBM. For example, the N-terminal residue Ser19 of hACE2 forms a new hydrogen bond with the Ala475 backbone of SARS-CoV-2 RBM, and the Gln24 of the N-terminal helix of hACE2 also forms a new contact with SARS-CoV. -2 RBM. When compared to Leu472 from SARS-CoV-2RBM, Phe486 from SARS-CoV-2 RBM points in a different direction and forms a hydrophobic region involving Met82, Leu79 and Tyr83 from hACE2 (Figure 1).
Comparison with SARS-CoV-2RBM shows that these small structural changes of SARS-CoV-2 RBM are more favorable for hACE2 binding. They are subtle differences, but very relevant from a functional point of view. Two critical binding sites (virus binding hotspots) have been revealed, the hotspot-31 critical point on the Lys31 and Glu35 salt bridge, and the 353 hotspot on another salt bridge between Lys353 and Asp38. These two salt bridges are weak, due to the great distance in the interaction, but being enclosed in a hydrophobic environment, which reduces the effective dielectric constant, their binding energy is higher (Figure 2).
To confirm these structural findings, biochemical studies of the RBD/ hACE2 binding affinity have been performed after introducing certain mutations in SARS-CoV-2 RBD. These mutations suggest that the bat coronavirus RaTG13 could infect humans (supporting the zoonotic origin of the epidemic). Furthermore, the RBMs of SARS-CoV-2 and bat-COV RaTG13 contain a similar motif of four residues in the ACE2-binding ridge, supporting that one has evolved from the other. In addition, to enhance hACE2 recognition, SARSCoV- 2 exhibits two changes in the L486F and Y493Q residues of RaTG13, which appear to have facilitated the transmission of SARS-CoV-2 from bat to humans. Therefore, there may not be an intermediate host between the bat and the human in COVID-19, unlike what happened with SARS and MERS. of course, for now it is impossible to rule out the existence of a mediator, which could well be a pangolin or other wild animal sold in the Wuhan market; In the case of the pangolin, it is necessary to sequence more genomes of the pangolin coronavirus to clarify the issue, but so far a genomic similarity of more than 99% has been evidenced between them .
In conclusion, knowing the disposition of the areas where the amino acids sensitive to oxidation by chlorine dioxide are located, highlighting that the spike protein of the SARS-CoV-2 coronavirus contains 54 tyrosine, 12 tryptophan, 40 residues of cysteine, in addition to proline, which in turn is present in the structure of ACE2 in connection with RBD, allows projecting the actions of chlorine dioxide on the viral spike. The best pedagogical example is that the spike is the key and the ACE2 the lock. The deformation of the key by oxidation of chlorine dioxide in the amino acids cysteine, tyrosine, tryptophan and proline, of the helix chains and of the oxidation of the lock (ACE2) prevent not only the union, but also dissolve the existing union between the spike (RBD) and ACE, very quickly.
We want to express our gratitude for your collaboration and contributions to the doctor Dr. Mitchell B. Liester, University of Colorado School of Medicine, Colorado Springs Branch, Monument, CO 80132.
This work was supported with the researchers' own resources.
Kalcker, Andreas declares a possible financial interest as he is the inventor of the Swiss patent pending/11136-CH. The other two authors have no competing economic interests. This does not alter the authors' adherence to all policies on the exchange of data and materials.